Genetic aspects of decreased low-density lipoprotein cholesterol values

QR Code

Genetic aspects of decreased low-density lipoprotein cholesterol values

Aim. To study genetic causes of decreased low-density lipoprotein cholesterol (LDL-C) in Russian patients.Material and methods. The study included the following Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) participants: individuals with LD...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. N. Meshkov, A. I. Ershova, A. V. Kiseleva, V. I. Mikhailina, S. A. Smetnev, А. G. Soplenkova, V. A. Kutsenko, Е. A. Sotnikova, Yu. V. Vyatkin, A. A. Zharikova, M. Zaichenoka, V. E. Ramensky, O. P. Skirko, M. S. Pokrovskaya, O. A. Litinskaya, S. A. Shalnova, O. M. Drapkina
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2023-12-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	apob apoc3 pcsk9 hypocholesterolemia low-density lipoprotein cholesterol genetic risk score
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/3846
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Role of Cholesterol in Assessing the Condition of the Surgical Patients
by: Ralitsa Stavrova-Hristova
Published: (2019-12-01)

New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01)

Lipoprotein (a) and apolipoprotein BD100 in coronary heart disease pathogenesis
by: K. I. Tebloev, et al.
Published: (2005-10-01)

Phenotypical features of heterozygous familial hypercholesterolemia in individuals with LDLR or APOB gene mutations
by: A. N. Meshkov, et al.
Published: (1970-01-01)

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
by: A. E. Nikitin, et al.
Published: (2020-03-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)

HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW
by: M. G. Bubnova
Published: (2018-07-01)

Validation of genetic risk scores for obesity on a sample of the population of Russian regions
by: A. V. Kiseleva, et al.
Published: (2023-11-01)

Validation of genetic risk scores for type 2 diabetes on a Russian population sample from the biobank of the National Medical Research Center for Therapy and Preventive Medicine
by: A. V. Kiseleva, et al.
Published: (2023-12-01)

Atherosclerosis and inflammation – the path from pathogenesis to treatment: review of the current state of the issue (part 2)
by: A. A. Avagimyan, et al.
Published: (2025-07-01)

LIPID PROFILE AND GENETIC MARKERS ASSOCIATED WITH THE LEVEL OF OXIDIzED LOW DENSITY LIPOPROTEIDES
by: E. Yu. Khlebus, et al.
Published: (2017-11-01)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
by: A. V. Blokhina, et al.
Published: (2022-01-01)

Observational study of inclisiran effectiveness in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2023-12-01)

ASSOCIATION OF POLYMORPHISMS GLN192ARG PON1 AND S3238G APOC3 IN WOMEN WITH CORONARY HEART DISEASE AND DIABETES MELLITUS TYPE 2 AND HYPOTHYROIDISM
by: A. P. Fyodorova, et al.
Published: (2017-08-01)

Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2024-06-01)

SELECTION FOR BEHAVIOR AND CORRELATION WITH THE MACROGLOBULINE AND LYPOPROTEINE SYSTEMS IN THE AMERICAN MINK (NEOVISON VISON)
by: V. I. Ermolaev, et al.
Published: (2015-01-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

Comparative effectiveness of different methods of prescribing rosuvastatin and ezetimibe in combination with PCSK9 inhibitors
by: A. A. Kuznetsov, et al.
Published: (2024-06-01)

In silico identification of novel gene biomarkers in Liver Hepatocellular Carcinoma (LIHC) with specialized epigenetics informatics tools
by: Mohamad Zafran AMINUDDIN, et al.
Published: (2025-06-01)

Relationship of sortilin and proprotein convertase subtilisin/kexin type 9 in blood serum with the severity of carotid and coronary atherosclerosis in hypertensive patients
by: Yu. Yu. Vukolova, et al.
Published: (2022-06-01)

Search and replication of associations of genome variants with lipid levels in a Russian sample
by: M. Zaichenoka, et al.
Published: (2023-12-01)

Validation of genetic risk scores for hypertension in the Central Russian population
by: A. S. Limonova, et al.
Published: (2023-12-01)

Value of proprotein convertase subtilisin/kexin type 9 and inflammatory markers in the diagnosis of carotid atherosclerosis in hypertensive men
by: Yu. Yu. Vukolova, et al.
Published: (2024-10-01)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01)

Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues
by: M. V. Zhuravleva, et al.
Published: (2020-09-01)

СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИ
by: С. С. Бажан
Published: (2013-12-01)

Lipid Profile, PCSK9, ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High‐Grade Prostate Cancer and Men At‐Risk of Prostate Cancer
by: Ann‐Charlotte Bergeron, et al.
Published: (2025-02-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders
by: S. A. Shalnova, et al.
Published: (2022-09-01)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023-12-01)

Effect of combined lipid-lowering therapy on atherosclerotic plaque vulnerability in patients with acute coronary syndrome (Combi-LLT ACS): randomized trial protocol
by: A. N. Kovalskaya, et al.
Published: (2022-12-01)

FEATURES OF CORONARY ARTERIES LESION AT UNSTABLE ANGINA PATIENTS DEPENDING ON DISTRIBUTION OF APO С-III GENE POLYMORPHISM AND TYPE OF DISLIPIDEMIA
by: A. S. Eshpulatov, et al.
Published: (2014-09-01)

Features of lipid-lowering therapy in liver transplant recipients
by: A. A. Kucherov, et al.
Published: (2023-12-01)

Intensification of lipid-lowering therapy in very high-risk patients: potential of combination with PCSK9 inhibitors
by: D. Yu. Sedykh, et al.
Published: (2022-07-01)

THE INFLUENCE OF HYPOLIPIDEMIC THERAPY ON THE LEVEL OF MODIFIED LOW DENSITY LIPOPROTEIDES
by: V. Z. Lankin, et al.
Published: (2018-09-01)

Impact of non-high-density lipoprotein cholesterol in mortality and cardiovascular events among middle-aged Russian men: 40 years ago and now
by: S. A. Shalnova, et al.
Published: (2024-12-01)

Association of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and sarcopenia in elderly adults
by: Yi Lin, et al.
Published: (2025-06-01)

Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients
by: Yeyan Lei, et al.
Published: (2025-07-01)

ANGPTL3, ANGPTL4, APOA5, APOB, APOC2, APOC3, LDLR, PCSK9, LPL gene variants and coronary artery disease risk
by: A. N. Meshkov, et al.
Published: (2022-11-01)

Use of polygenic risk scores for differential diagnostics for patients with clinical diagnosis of familial hypercholesterolemia
by: M. Zaychenoka, et al.
Published: (2025-02-01)